[go: up one dir, main page]

PE20020510A1 - DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT) - Google Patents

DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)

Info

Publication number
PE20020510A1
PE20020510A1 PE2001000944A PE2001000944A PE20020510A1 PE 20020510 A1 PE20020510 A1 PE 20020510A1 PE 2001000944 A PE2001000944 A PE 2001000944A PE 2001000944 A PE2001000944 A PE 2001000944A PE 20020510 A1 PE20020510 A1 PE 20020510A1
Authority
PE
Peru
Prior art keywords
alkyl
azepyl
serotonin
receptors
derivatives
Prior art date
Application number
PE2001000944A
Other languages
English (en)
Inventor
Kristine M Frank
Jian-Min Fu
Brad A Acker
Jed F Fisher
Mcwhorter
Rogier
Jeanette K Morris
Eric Jon Jacobsen
Michael D Ennis
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20020510A1 publication Critical patent/PE20020510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C8, ENTRE OTROS; R2 ES ALQUILO C1-C8, OH; R3 ES H, ALQUILO C1-C8, Ar, HET, R7C(=O), ENTRE OTROS; R4 ES Ar, ALQUILO C1-C8, ArO-, ALCOXI C1-C8, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, HALOALQUILO, ENTRE OTROS; R7 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; p ES 0-4; q ES 0-10. SON COMPUESTOS PREFERIDOS (5aS*,10bS*)-10-(2-ETOXIFENIL)-1,2,3,4,5,5a,6,10b-OCTAHIDROAZEPINO[4,5-b]INDOL, (5aS,10bS)-10-(2-ETOXIFENIL)-1,2,3,4,5,5a,6,10b-OCTAHIDROAZEPINO[4,5-b]INDOL, (5aS,10bS)-10-(2-ETOXIFENIL)-1,2,3,4,5,5a,6,10b-OCTAHIDROAZEPINO[4,5-b]INDOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT) Y SON UTILES PARA EL TRATAMIENTO DE ANSIEDAD, DEPRESION, ESQUIZOFRENIA, EPILEPSIA
PE2001000944A 2000-09-20 2001-09-20 DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT) PE20020510A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23437600P 2000-09-20 2000-09-20
US26604701P 2001-02-01 2001-02-01
US30196401P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
PE20020510A1 true PE20020510A1 (es) 2002-06-12

Family

ID=27398561

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2001000944A PE20020510A1 (es) 2000-09-20 2001-09-20 DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE2001000945A PE20020443A1 (es) 2000-09-20 2001-09-20 DERIVADOS AZEPINO [4,5-b] INDOL SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE SEROTONINA 5HT

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2001000945A PE20020443A1 (es) 2000-09-20 2001-09-20 DERIVADOS AZEPINO [4,5-b] INDOL SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE SEROTONINA 5HT

Country Status (7)

Country Link
US (4) US6586421B2 (es)
EP (2) EP1319004A2 (es)
JP (2) JP2004509893A (es)
AR (2) AR034264A1 (es)
AU (2) AU2001292898A1 (es)
PE (2) PE20020510A1 (es)
WO (2) WO2002024701A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532619A (ja) * 2001-02-16 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー 細胞内シグナル伝達カスケードに関与する新規なヒト遺伝子ｒｅｔ１６の同定およびクローニング
EP1281700A1 (en) * 2001-07-31 2003-02-05 Resolution Research Nederland B.V. Manufacturing process for the preparation of alpha, alpha-branched alkane carboxylic acids providing esters with an improved softness
US6849640B2 (en) 2001-08-08 2005-02-01 Pharmacia & Upjohn Company Therapeutic 1H-pyrido [4,3-b] indoles
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US7592454B2 (en) * 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
CA2565683C (en) * 2004-06-30 2013-04-02 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
NZ569554A (en) * 2006-01-19 2011-10-28 Athersys Inc Thiophenyl and pyrrolyl azepines as serotonin 5-HT2C receptor ligands and uses thereof
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2009035574A1 (en) * 2007-09-10 2009-03-19 Merck & Co., Inc. Method for measuring mitochondrial membrane potential in vertebrate cells
US7816435B2 (en) * 2007-10-31 2010-10-19 Momentive Performance Materials Inc. Halo-functional silane, process for its preparation, rubber composition containing same and articles manufactured therefrom
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2009089482A1 (en) 2008-01-11 2009-07-16 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
PA8843701A1 (es) 2008-09-29 2010-05-26 Abbott Lab Derivados de indolina y métodos para usarlos
WO2010051503A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US20130172320A1 (en) * 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
BR112013021126A2 (pt) 2011-02-18 2019-09-24 Medivation Technologies Inc método para reduzir a pressão sanguínea, método para aumentar o fluxo sanguíneo renal ou diminuir a reabsorção de sódio, método para tratar uma doença, kit, composto e composição farmacêutica
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
US20130178618A1 (en) * 2012-01-10 2013-07-11 William Allen Boulanger Novel pharmaceutical intermediates and methods for preparing the same
WO2014031167A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
JP7132939B2 (ja) 2017-03-24 2022-09-07 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規組成物および方法
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
JP7546546B2 (ja) 2018-08-31 2024-09-06 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
EP3931189A4 (en) * 2019-02-27 2022-11-30 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
KR20210134928A (ko) 2019-02-27 2021-11-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 n-치환된 인돌 및 다른 헤테로사이클
CN111053789A (zh) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 调节免疫系统的方法和组合物
US20230257385A1 (en) 2021-11-17 2023-08-17 Terran Biosciences Inc. Salt and solid forms of tabernanthalog
CA3239565A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
WO2023122135A1 (en) * 2021-12-22 2023-06-29 Kuleon Llc Serotonin receptor agonists and methods of making and using the same
US20250296934A1 (en) * 2022-05-06 2025-09-25 Bright Minds Biosciences Inc. Azepinoindoles and methods of preparation thereof
US12116372B1 (en) 2023-12-14 2024-10-15 William Allen Boulanger Process for preparing methyl 3-bromo-2-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propanoate

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6699E (fr) 1905-09-25 1907-01-31 Maurice Honore Firmin Muraire Machine à enfiler les cocons de vers à soie
DE1062840B (de) 1953-03-03 1959-08-06 Siemens Reiniger Werke Ag Eirichtung zur Sichtbarmachung usichtbarer, bzw. zur Verstaerkung sichtbarer,durch Korpuskular- oder Wellenstrahlung hervorgerufener Bilder, insbesondere fuer Roentgendurchleuchtungen
CH445508A (de) * 1964-12-03 1967-10-31 Geigy Ag J R Verfahren zur Herstellung von neuen Indolderivaten
GR35044B (el) * 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US3839357A (en) 1966-05-10 1974-10-01 Upjohn Co 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
US3525750A (en) 1966-05-31 1970-08-25 Geigy Chem Corp 1,2,3,4,5,6-hexahydro-azepino(4,5-b) indole derivatives
US3553232A (en) 1967-08-25 1971-01-05 Upjohn Co 4-(1,4,5,6-tetrahydroazepine(4,5-b)indole-3(2h)-yl)butyrophenones
US3622673A (en) 1968-11-14 1971-11-23 Upjohn Co 4-(1,4,5,6-TETRAHYDROZEPINO 4,5-b INDOL-3(2H)-YL-BUTYROPHENON COMPOSITIONS AND PROCESS OF TREATMENT MENTAL OR EMOTIONAL DISORDERS
US3652588A (en) 1969-10-23 1972-03-28 Upjohn Co 6-alkyl-1 2 3 4 5 6-hexahydroazepino(4 5-b)indoles
US3676558A (en) 1970-08-28 1972-07-11 Upjohn Co Anorexigenic compositions comprising 6-alkyl-1,2,3,4,5,6-hexahydroazepino 4,5-indoles as active ingredient and process of treatment
US3776922A (en) 1972-03-24 1973-12-04 J Epstein Indole carboxaldehydes
DE3070467D1 (en) 1979-11-02 1985-05-15 Sandoz Ag Azepinoindoles, process for their production and pharmaceutical compositions containing them
CH649553A5 (de) * 1982-05-06 1985-05-31 Sandoz Ag Azepinoindole und verfahren zu deren herstellung.
JPS63163347A (ja) 1986-12-25 1988-07-06 Konica Corp 有機着色物質の光褪色防止方法
EP0377238A1 (en) 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
FR2663935A1 (fr) 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
IL147108A0 (en) 1999-06-15 2002-08-14 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
AU2001269781A1 (en) * 2000-07-06 2002-01-21 Pharmacia And Upjohn Company Substituted 2,3,7,8,9,10,11,12-octahydroazepino(4,5-b)pyrano(3,2-e) indoles

Also Published As

Publication number Publication date
WO2002024701A3 (en) 2002-06-13
WO2002024700A3 (en) 2002-06-13
US20030225058A1 (en) 2003-12-04
EP1319004A2 (en) 2003-06-18
US20020077318A1 (en) 2002-06-20
US6828314B2 (en) 2004-12-07
WO2002024700A2 (en) 2002-03-28
AU2001294606A1 (en) 2002-04-02
US20020107278A1 (en) 2002-08-08
AU2001292898A1 (en) 2002-04-02
US20030220321A1 (en) 2003-11-27
JP2004509894A (ja) 2004-04-02
AR034264A1 (es) 2004-02-18
PE20020443A1 (es) 2002-05-16
AR035493A1 (es) 2004-06-02
EP1319005A2 (en) 2003-06-18
US6903090B2 (en) 2005-06-07
JP2004509893A (ja) 2004-04-02
US6583135B2 (en) 2003-06-24
WO2002024701A2 (en) 2002-03-28
US6586421B2 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20030431A1 (es) DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
PE20020532A1 (es) Derivados de naftaleno como agonistas del receptor canabinoide
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR062965A1 (es) Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos
AR044038A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
AR067991A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR044037A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
PE20011259A1 (es) Derivado de piridina y pirimidina
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR044036A1 (es) Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
AR059076A1 (es) Tiofenil y pirrolil azepinas como ligandos del receptor 5-ht2c de serotonina y usos de las mismas
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE20081458A1 (es) DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS
PE20060610A1 (es) Derivados tetraciclicos como moduladores de los receptores de estrogeno
PE20141169A1 (es) Derivados de etinilo
PE20061144A1 (es) DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs)
PE20020882A1 (es) Derivados de piperidina como antagonistas selectivos de subtipos del receptor de n-metil-d-aspartato

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed